Biohaven Pharmaceutical Company
Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
Technology:
Others
Industry:
Biotechnology, Health Care, Science and Engineering
Headquarters:
New Haven, Connecticut, United States
Founded Date:
25 09 13
Employees Number:
501-1000
Funding Status:
IPO
Acquisitions Number:
1
Investors Number:
12
Total Funding:
443700000
Estimated Revenue:
$10M to $50M
Last Funding Date:
15 03 21
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership